<DOC>
	<DOCNO>NCT00963690</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy CloSys Hemostatic Device design stop bleeding interventional procedure .</brief_summary>
	<brief_title>Evaluation CloSys Closure System Adjunct Standard Compression</brief_title>
	<detailed_description>To analyze time hemostasis ( time stop bleeding ) , time ambulation ( time walk ) adverse event .</detailed_description>
	<mesh_term>Hemostatics</mesh_term>
	<criteria>General Inclusion Criteria All answer must YES eligible study : 1 . Subject ≥ 18 year age ; 2 . Subject willing able provide inform consent ; 3 . Subject able ambulate preprocedure without difficulty ; 4 . Subject able remain supine extended period time ; 5 . Subject willing able comply requirement study protocol , include followup visit evaluation ; General Exclusion Criteria All answer must NO eligible study : 1 . Subject systolic blood pressure ( SBP ) ≥ 160 mmHg despite medical therapy ; 2 . Subject diastolic blood pressure ( DBP ) ≥ 100 mmHg despite medical therapy ; 3 . Subject receive thrombolytic therapy , streptokinase , urokinase , retavase , tenecteplase , tPA , within 24 hour schedule procedure ; 4 . Subject lactating ; 5 . Subject life expectancy le one ( 1 ) year ; 6 . The percutaneous intervention emergent procedure ; 7 . Subject know coagulopathy disorder , include , limited , hemophilia , sickle cell disease , von Willebrand disease ; 8 . Subject know diagnosis autoimmune disease ; 9 . Subject know suspected diagnosis vasculitis ; 10 . Subject currently infection kind ; 11 . Subject either posterior Tibialis ( PT ) dorsalis pedis ( DP ) pulse doppler ipsilateral extremity ; 12 . Subject critical limb ischemia and/or severe peripheral vascular disease identify rest pain and/or gangrene ; 13 . Rutherford category five ( 5 ) six ( 6 ) ; 14 . Subject currently within last thirty ( 30 ) day participate another investigational drug device study ; 15 . Subject unavailable followup ; 16 . Subject know allergy previous intolerance Protamine Sulfate ; 17 . Subject know allergy shellfish ; 18 . Subject previous closure device ipsilateral side within last ninety ( 90 ) day ; 19 . Prior intervention surgical procedure access site within last six ( 6 ) month ; 20 . Subject plan intervention surgical procedure prior completion thirty ( 30 ) day followup visit ; 21 . Subject receive low molecular weight ( LMWH ) heparin , , Enoxaparin sodium ( Lovenox , Xaparin Clexane ) within past twelve ( 12 ) hour ; 22 . Body mass index ( BMI ) &gt; 45 &lt; 20 ; 23 . The investigator determine subject otherwise appropriate subject study ; 5.3.2.1 Laboratory Values Exclusion Criteria All answer must NO eligible study : Within seven ( 7 ) day prior interventional procedure accord standard care percutaneous interventional procedure require contrast angiography : 1 . Subject know , suspect , pregnant ( verified urine/blood pregnancy test ) ; 2 . Subject 's preprocedural platelet count &lt; 100,000 103/ul ; 3 . Subject 's hematocrit &lt; 28 % ; 4 . Subject 's hemoglobin &lt; 10 g/dL ; 5 . Subject 's serum creatinine ≥ 2.5 mg/dL ; 6 . Prothrombin Time ( PT ) within normal limit ; 7 . Partial Thromboplastin Time ( PTT ) within normal limit ; 8 . For subject take warfarin ( Coumadin ) : The subject warfarin within 30 day INR ≥ 1.8 time procedure ; post Interventional Procedure Inclusion Criteria All answer must YES eligible study : 1 . Subject undergone percutaneous interventional procedure utilize femoral arterial access ; 2 . Heparin administer anticoagulation procedure ; 3 . Subject ACT ≥ 225 second &lt; 350 second ; 4 . Subject 's arterial introducer sheath 5 Fr , 6 Fr 7 Fr ; 5 . Subject 's arterial introducer sheath overall length ≤ 15.0 cm ; 6 . Subject 's SBP &lt; 160 mmHg ; 7 . Subject 's DBP &lt; 100mmHg ; 8 . Subject 's physical , mental , clinical status stable allow ambulation assessment four ( 4 ) hour follow removal introducer sheath ; 5.3.4 Post Interventional Procedure Exclusion Criteria All answer must NO eligible study : 5.3.4.1 General Exclusion Criteria 1 . Subject experience cardiogenic shock , , immediately interventional procedure ; 2 . Subject bleed around sheath prior sheath removal ; 3 . Subject pseudoaneurysm sheath removal ; 4 . Subject palpable hematoma sheath removal ; 5 . Subject evidence retroperitoneal bleed prior sheath removal ; 6 . Subject experience double wall puncture vascular access ; 7 . Subject experienced multiple arterial puncture ( &gt; 1 ) vascular access ; 8 . Subject ipsilateral venous sheath ; 9 . Subject intraprocedural therapeutic thrombolysis ; 10 . Subject receive bivalirudin ( Angiomax® ) , , intervention ; 11 . Subject receive Protamine Sulfate IV reverse heparin receive procedure ; 12 . Subject suspect bacterial contamination access site ; 13 . Arterial access obtain near vascular graft ; 14 . Subject 's percutaneous intervention treatment acute myocardial infarction ( MI ) ; Angiographic Eligibility Criteria Angiographic Inclusion Criteria All answer must YES eligible trial : 1 . Arterial access obtain femoral bifurcation ; 2 . Arterial access obtain inguinal ligament ; Angiographic Exclusion Criteria All answer must NO eligible trial : 1 . Common femoral artery &gt; 50 % narrow due calcification plaque ; 2 . Arteriovenous fistula present ; 3 . Other complication note femoral angiogram .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>